Jan 25,2022

Alira Health Expands its Digital Health Portfolio with the Acquisition of Self Care Catalysts

Alira Health, a global healthcare consulting and technology firm, announced that it has acquired Self Care Catalysts, Inc., a digital health company headquartered in Toronto, Canada. Self Care Catalysts’ digital health platform, Health Storylines™, helps patients gain an intimate understanding of their health journey while managing their conditions and generating clinical and real-world evidence along the way. Health Storylines enables over 120,000 patients to be active and informed owners of their healthcare data across more than thirty major therapeutic areas. This is Alira Health’s third patient-centric digital health acquisition in the last four months and the first in North America.

COLLABORATION MERGERS & ACQUISITION

#product & service

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 08,2022

Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer’s Disease

Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world evidence (RWE) technology and analytics provider, today announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment (MCI) and Alzheimer’s disease. This first-in-class predictive model would accelerate clinical development for Cognito's late-stage clinical program in mild-to-moderate MCI and Alzheimer’s disease by identifying patients who may benefit from treatment earlier.

COLLABORATION PARTNERSHIP

#r&d

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 28,2022

AppliedVR and Komodo Health Partner To Validate Power of Virtual Reality As Effective Digital Therapy for Chronic Pain

Komodo Health today announced a new partnership with AppliedVR, the leader in therapeutic virtual reality (VR) for pain management. The FDA recently granted AppliedVR’s De Novo request for its flagship product, RelieVRx, and is now tapping into Komodo’s technology platform to further demonstrate the therapeutic impact of RelieVRx for patients living with chronic lower back pain. Using Komodo’s technology, AppliedVR will combine its proprietary insights with Komodo’s real-world data to conduct clinical research into the efficacy, cost savings, and health system value that RelieVRx delivers compared to traditional chronic pain treatment modalities.

COLLABORATION PARTNERSHIP

#product & service

#virtual reality

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Pear Presents Interim Real-World Data Showing Significant Reductions In Symptoms Of Chronic Insomnia, Anxiety And Depression With Somryst® At Sleep 2022

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced interim follow-up real-world data from DREAM, a remote, decentralized trial, that showed treatment with Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and six months later. Interim data from the DREAM study (NCT04325464), a remote, virtual, open-label, decentralized clinical trial evaluating Somryst, analyzed in mid-Q1 2022, included 993 adult patients (22-75 years of age) enrolled to date with chronic insomnia living in the U.S. who had access to a mobile device. As part of its PearCreate™ platform, Pear has developed its own remote, decentralized, virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which was used for the DREAM study.

CLINICAL STUDY

#pdt

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Diabetes Reversal Leader Virta Health Showcases Transformative, Long-Lasting Cardiometabolic Health Improvements for Veteran Patients

Today, Virta Health, the type 2 diabetes reversal leader, announced two-year patient outcomes from its multi-year partnership with the Department of Veterans Affairs (VA). The results, presented at the American Diabetes Association 82nd Scientific Sessions, highlight broad metabolic health improvements for Veteran patients, including long-term blood sugar reduction, clinically-significant weight loss, and medication deprescription.

CLINICAL STUDY

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia. The analysis evaluated real-world data of 248 adult patients with chronic insomnia treated with Somryst over 24-months compared to the 24-months months prior to treatment and found: Reductions in health-related services; An estimated $2,059 reduction in per-patient costs; 37.2% reduction in mean insomnia severity index (ISI) score (19.1 at baseline and 12.0 at nine weeks).

CLINICAL STUDY

#pdt

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 05,2022

Results presented at ESMO 2022: Kaiku Health digital patient monitoring platform can help in resolving acute fever in melanoma patients

A multicenter study led by the Netherlands Cancer Institute used Kaiku Health digital patient management platform to investigate the use of digital patient monitoring and support of patients with advanced melanoma. The results published at ESMO 2022 annual conference suggest that Kaiku Health can be used to support patients and to collect real-world evidence. They can also help to understand the development of symptoms and quality of life of the patients.

CLINICAL STUDY

#rwe

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 24,2022

Pear Therapeutics Announces Publication Of Real-World Data Showing High Rates Of Engagement, Retention And Abstinence With Reset®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of results from a real-world observational analysis of engagement, retention and substance use among patients with substance use disorder (SUD) treated with reSET®, the first and only FDA-authorized PDT for the treatment of SUD (including alcohol, cannabis, cocaine, and stimulants like methamphetamines). The real-world data, which demonstrated high rates of engagement, retention and abstinence from substances with reSET treatment through 12 weeks, was published in The American Journal on Addictions (AJA).

CLINICAL STUDY

#pdt

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 02,2021

From Theory to Real-World Practice: Clinical Integration of Digital Therapeutics

Digital therapeutics (DTx) is a new category of medicine that refers to treatments delivered directly to patients via software or apps. The scope of DTx encompasses treatment, management, and prevention of a broad spectrum of diseases and disorders. As such, DTx are part of a larger ecosystem of digital health technologies that provides support for patients, clinicians, and medical institutions. These technologies include patient- and clinician-platforms, as well as the unseen operational components.

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 24,2021

Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network (“Catalyst”), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes. Catalyst joins the Colorado Prevention Center in the study of BT-001, an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

COLLABORATION PARTNERSHIP

#r&d

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWE